# Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

> **NCT00385736** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 576 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** adalimumab
- **BIOLOGICAL:** adalimumab
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00385736
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-04
- **Final completion:** 2010-03
- **Target enrollment:** 576 (ACTUAL)
- **Last updated:** 2011-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00385736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00385736, "Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00385736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*